ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 76

Effect of Ifnα and Costimulatory Blockade on Brain Infiltration in a Model of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’

Hadijat Makinde1, Chirag Raparia 2, Anne Davidson 2 and Carla Cuda 3, 1Northwestern University, Chicago, IL, 2Feinstein Institutes for Medical Research, Manhasset, 3Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, IL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: innate immunity, Macrophage, neurologic involvement and animal models, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Animal Models Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects many end organs including the brain. Despite a prevalence of over 50% in SLE patients, neuropsychiatric symptoms of SLE (NPSLE) are among the least understood complications. Similar to SLE patients, the lupus-prone NZB/W strain develops NPSLE-like disease that manifests in mood-related disorders and learning impairment. Despite the paucity of data examining underlying mechanisms, accumulating evidence points to microglia, the resident innate immune cells in the brain, as a driver of disease. The cross-talk between infiltrating monocyte-derived macrophages and microglia plays a critical role in directing microglial responses. Evidence shows that IFNα exacerbates systemic disease and induces early lethality in the NZB/W strain in a T cell-mediated manner. In contrast, blocking the CD28/cytotoxic T lymphocyte antigen (CTLA)-4/B7 interaction (using CTLA4Ig) induces disease remission in NZB/W mice in combination with anti-CD40L antibodies and cyclophosphamide. Here, we elucidate the role of IFNα administration and costimulatory blockade on the infiltration of monocyte-derived macrophages and the corresponding microglial responses in NPSLE-like disease.

Methods: One cohort of female NZB/W mice (n= 5) was given a single intravenous injection of adenovirus-IFNα (AD-IFNα) at 12-14 wks of age and tissues were harvested at 18 wks. An additional cohort (n=5) was intraperitoneally injected 3 times/wk for 2 wks with CTLA4Ig/anti-CD40L (costimulatory blockade) at 18-20 wks prior to overt disease and tissues were harvested at 32 wks. Treated animals and age-matched NZB/W control mice were examined for proteinuria and splenic alterations as an indicator of systemic disease. Brain monocytic infiltration was evaluated via flow cytometry as a measure of blood-brain barrier breach. Neurocognitive testing and RNA-seq analysis of sorted microglia are pending.

Results: Mice immunized with AD-IFNα developed proteinuria and splenomegaly, corresponding to an increase in total splenocyte numbers, compared to age-matched control NZB/W mice. In contrast, costimulatory blockade prevented development of proteinuria and splenomegaly compared to their age-matched counterparts. Similar to SLE patients with NPSLE, AD-IFNα-immunized mice showed reduced brain volume compared to age-matched control mice. However, animals placed on the costimulatory blockade treatment showed a trend towards prevention of this brain volume loss compared to age-matched control mice. Furthermore, the increased macrophage infiltration into brains of 18-wk-old AD-IFNα-immunized mice mirrored that found in brains of 32-wk-old NZB/W control mice. Strikingly, costimulatory blockade prevented this infiltration at 32 wks.

Conclusion: These data indicate that IFNα accelerates brain macrophage infiltration, potentially impacting repair and regeneration responses of microglia within the injured brain, while costimulatory blockade prevents this insult. Future studies will examine neurocognitive decline and microglial-specific responses to these treatments.


Disclosure: H. Makinde, None; C. Raparia, None; A. Davidson, None; C. Cuda, None.

To cite this abstract in AMA style:

Makinde H, Raparia C, Davidson A, Cuda C. Effect of Ifnα and Costimulatory Blockade on Brain Infiltration in a Model of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’ [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-ifn%ce%b1-and-costimulatory-blockade-on-brain-infiltration-in-a-model-of-neuropsychiatric-symptoms-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-ifn%ce%b1-and-costimulatory-blockade-on-brain-infiltration-in-a-model-of-neuropsychiatric-symptoms-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology